
    
      Multicenter, open-label, single-arm, phase I-II pilot study in which a m√≠nimum of 20 patients
      will enter the study with the primary objective to assess the safety and secondary objective
      to assess efficacy in relation to immune reconstituation followed by a new platform of
      treatment consisting of initial cord blood unit 80 fraction transplantation, followed by a
      prophylactic donor lymphocite infusion (DLI) of the fraction 20 of the cord blood unit. The
      second infusion will take place between 60 and 90 days after transplantation.
    
  